(Q37845703)

24 August 2017

1 reference

title

Dyslipidemia in HIV-infected individuals (English)

1 reference

24 August 2017

0 references

1 reference

Eduardo Sprinz

1

1 reference

24 August 2017

Rosmeri Kuhmmer Lazzaretti

series ordinal

2

1 reference

24 August 2017

Regina Kuhmmer

series ordinal

3

1 reference

24 August 2017

Jorge Pinto Ribeiro

series ordinal

4

1 reference

24 August 2017

publication date

1 November 2010

1 reference

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

24 August 2017

published in

1 reference

24 August 2017

volume

14

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

575-588

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Dramatic improvement in survival among adult Brazilian AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Improved survival in HIV-infected persons: consequences and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Fat distribution and metabolic changes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

CD4+ count-guided interruption of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy 'Diet FRS Study'.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

The composition of the Eskimo food in north western Greenland

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Reduction in Triglyceride Level With N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Effectiveness of lipid-lowering therapy in HIV patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970115-X

7 January 2021

10.1016/S1413-8670(10)70115-X

Identifiers

DOI

1 reference

24 August 2017

1 reference